NDAINTRAVENOUS, SUBCUTANEOUSINJECTABLEPriority Review
Approved
Mar 1993
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
13
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOVENOX (enoxaparin sodium) is a low-molecular-weight heparin (LMWH) anticoagulant administered via subcutaneous or intravenous injection. It is indicated for thromboembolism prophylaxis and treatment across multiple settings including orthopedic surgery, acute coronary syndromes, and venous thromboembolism. The drug works by potentiating antithrombin III to inhibit Factor Xa and thrombin, preventing clot formation.
LOE Approaching
Established mature asset approaching loss of exclusivity with moderate competitive pressure (45/100); brand team focus shifting to lifecycle extension and generic transition strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients
Started Jun 2023
220 enrolled
Safety IssuesEffect of Drug
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
Started Apr 2015
400 enrolled
Gynecologic CancerVenous Thromboembolism
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Started Feb 2014
606 enrolled
TraumaSurgeryDeep Vein Thrombosis (DVT)+1 more
Efficacy and Safety of the LovenoxTM (Enoxaparin) Versus HeparinTM Gynecologic Oncology Patients
Started Oct 2009
150 enrolled
Malignant Female Reproductive System Neoplasm
A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)
Started Jul 2008
0Small Cell Lung Cancer
Worked on LOVENOX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.